Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CCRN
CCRN logo

CCRN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cross Country Healthcare Inc (CCRN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.220
1 Day change
0.15%
52 Week Range
14.990
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CCRN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants an immediate entry. The stock is essentially flat, technicals are mixed, there is no fresh news catalyst, analyst sentiment is not provided, and the proprietary trading signals show no buy setup today. I would not buy it now; I would hold off and wait for a clearer catalyst or stronger momentum.

Technical Analysis

Current price is 13.195, essentially unchanged from the previous close at 13.2. The trend is mixed: SMA_5 > SMA_20 > SMA_200 is bullish and suggests the longer-term structure is constructive, but MACD histogram is -0.0627 and negatively contracting, which points to weakening near-term momentum. RSI_6 at 58.374 is neutral to slightly positive, so the stock is not oversold or in an obvious breakout condition. Price is sitting right around pivot support/resistance with very tight levels: Pivot 13.195, R1 13.222, S1 13.169. That indicates no strong directional edge right now. The short-term modeled trend also looks modest, with only small expected upside over the next day/week/month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish based on the open interest put-call ratio of 0.57, meaning call interest exceeds put interest. However, option volume is zero, so there is no active trading confirmation today. Implied volatility is extremely high at 242.62 with IV percentile at 99.21 and IV rank at 86.51, showing options are expensive and expectations are elevated. Overall options data leans bullish in positioning but does not provide a strong timing signal for a new long-term buy.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
11

Positive Catalysts

  • ["Bullish moving average alignment: SMA_5 > SMA_20 > SMA_200.", "Options positioning leans slightly bullish with put-call open interest ratio at 0.57.", "Stock pattern analysis suggests a small positive drift over the next week and month.", "No recent negative news in the last week."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no clear event-driven catalyst.", "MACD histogram is below zero and negatively contracting, suggesting weakening short-term momentum.", "No AI Stock Picker signal and no recent SwingMax signal.", "Insider activity is neutral and hedge funds are neutral.", "No recent congress trading data.", "Option volume is zero, so there is no live sentiment confirmation.", "Financial snapshot data is unavailable, limiting visibility into latest quarterly fundamentals."]

Financial Performance

Latest quarterly financial data was not available due to an error, so there is no usable snapshot of revenue, earnings, or growth trends. The latest quarter season cannot be confirmed from the provided data. Because of that, there is no fundamental evidence here to support an immediate long-term purchase.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of a recent upward revision or strong Wall Street consensus. Based on the available information, Wall Street pros appear neutral at best: there is no clear bullish catalyst, no fresh upgrades, and no price target momentum. The main positive is the constructive moving average setup, while the main negatives are the lack of news, absent financial detail, and weak momentum indicators.

Wall Street analysts forecast CCRN stock price to fall
8 Analyst Rating
Wall Street analysts forecast CCRN stock price to fall
1 Buy
7 Hold
0 Sell
Hold
Current: 13.200
sliders
Low
8.65
Averages
9.66
High
11
Current: 13.200
sliders
Low
8.65
Averages
9.66
High
11
Wedbush
Neutral -> Outperform
upgrade
$11 -> $15
AI Analysis
2026-03-19
Reason
Wedbush
Price Target
$11 -> $15
AI Analysis
2026-03-19
upgrade
Neutral -> Outperform
Reason
Wedbush upgraded Cross Country Healthcare to Outperform from Neutral with a price target of $15, up from $11.
Wedbush
Perform -> Outperform
upgrade
$11 -> $15
2026-03-19
Reason
Wedbush
Price Target
$11 -> $15
2026-03-19
upgrade
Perform -> Outperform
Reason
As previously reported, Wedbush upgraded Cross Country Healthcare to Outperform from Perform with a price target of $15, up from $11, following a management meeting that increased the firm's conviction in "the timing and achievability" of the company's revenue stabilization expectations, profitability recovery and tech-enabled strategic pivot. Additionally, the recent pullback in shares creates a positively skewed risk/reward profile, Wedbush adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CCRN
Unlock Now

People Also Watch